Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Arias Montano. Repositorio Institucional de la Universidad de Huelva
Publicación Artículo científico (JournalArticle)

Helicobacter pylori Antibody Reactivities and Colorectal Cancer Risk in a Case-control Study in Spain

  • Fernandez de Larrea-Baz, Nerea
  • Tejada, Antonio
  • Aragonés, Nuria
Background: Several studies have suggested that Helicobacter pylori (H. pylori) infection is a risk factor for colorectal cancer (CRC), while others have not confirmed this hypothesis. This work aimed to assess the relation of CRC with H. pylori seropositivity and with seropositivity to 16 H. pylori proteins, in the MultiCase-Control study, MCC-Spain. Methods: MCC-Spain is a multicase-control study carried out in Spain from 2008 to 2013. In total, 2,140 histologically-confirmed incident CRC cases and 4,098 population-based controls were recruited. Controls were frequency-matched by sex, age, and province. Epidemiological data were collected through a questionnaire fulfilled by face-to-face interviews and a self-administered food-frequency questionnaire. Seroreactivities against 16 H. pylori proteins were determined in 1,488 cases and 2,495 controls using H. pylori multiplex serology. H. pylori seropositivity was defined as positivity to >= 4 proteins. Multivariable logistic regression mixed models were used to estimate odds ratios (OR) and 95% confidence intervals (CI). Results: H. pylori seropositivity was not associated with increased CRC risk (OR = 0.91; 95% CI: 0.71-1.16). Among H. pylori seropositive subjects, seropositivity to Cag delta showed a lower CRC risk, and risk decreased with increasing number of proteins seropositive. Seropositivity to the most recognized virulence factors, CagA and VacA, was not associated with a higher CRC risk. No statistically significant heterogeneity was identified among tumor sites, although inverse relations were stronger for left colon cancer. An interaction with age and sex was found: H. pylori seropositivity was associated with a lower CRC risk in men younger than 65 and with a higher risk in older women. Conclusions: Our results suggest that neither H. pylori seropositivity, nor seropositivity to the virulence factor CagA are associated with a higher CRC risk. A possible effect modification by age and sex was identified.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Effectiveness of an intervention for improving drug prescription in primary care patients with multimorbidity and polypharmacy: Study protocol of a cluster randomized clinical trial (Multi-PAP project)

  • Prados-Torres, A.
  • del Cura-González, I.
  • Prados-Torres, D.
  • López-Rodríguez, J.A.
  • Leiva-Fernández, F.
  • Calderón-Larrañaga, A.
  • López-Verde, F.
  • Gimeno-Feliu, L.A.
  • Escortell-Mayor, E.
  • Pico-Soler, V.
  • Sanz-Cuesta, T.
  • Bujalance-Zafra, M.J.
  • Morey-Montalvo, M.
  • Boxó-Cifuentes, J.R.
  • Poblador-Plou, B.
  • Fernández-Arquero, J.M.
  • González-Rubio, F.
  • Ramiro-González, M.D.
  • Coscollar-Santaliestra, C.
  • Martín-Fernández, J.
  • Barnestein-Fonseca, M.P.
  • Valderas-Martínez, J.M.
  • Marengoni, A.
  • Muth, C.
  • Aza-Pascual-Salcedo, M.
  • Poncel-Falcó, A.
  • Bandrés-Liso, A.C.
  • Alcaraz-Borrajo, M.
  • Ruiz-San-Basilio, J.M.
  • Mataix-San-Juan, A.
  • López-León, A.M.
  • Mateos-Sancho, C.
  • Gimeno-Miguel, A.
  • Hernández-Santiago, V.
  • García de Blas, F.
  • García-Agua, N.
  • Rodríguez-Barrientos, R.
  • Vázquez-Alarcón, R.
  • Laguna-Berna, C.
  • Márquez-Chamizo, M.I.
  • Marta-Moreno, J.
  • Azcoaga-Lorenzo, A.
  • Abad-Díez, J.M.
  • Sánchez-Perruca, L.
  • Polentinos-Castro, E.
  • Clerencia-Sierra, M.
  • Ariza-Cardiel, G.
  • González-González, A.I.
  • Rico-Blázquez, M.
  • Rogero-Blanco, M.
  • Tello-Bernabé, M.E.
  • Álvarez-Villalba, M.
  • Rumayor-Zarzuelo, M.
  • del Pozo, C.S.C.
  • Torrente Garrido, J.I.
  • Aranda, C.G.
  • Lafuente, M.P.
  • Delgado Marroquín, Ma.Teresa
  • Molina, M.J.G.
  • Bernal, J.C.
  • Martín, M.V.A.
  • Domínguez, S.G.
  • Gorbea, C.B.
  • Negre, A.L.O.
  • Royo, E.G.
  • Taira, M.B.A.
  • Gutiérrez, J.F.T.
  • Quintana, J.P.
  • Miguel, V.M.
  • de las Heras, E.M.
  • Algora, C.E.
  • de Letosa, M.T.M.N.
  • Gascón del Prim, Elena
  • Delgado, N.S.
  • Sanjuan Cortés, Ma Rosario
  • Sánchez, T.C.
  • Lucas, E.D.
  • Mínguez Sorio, M.P.
  • Marzal, A.C.
  • García, E.D.
  • Álvarez, J.C.G.
  • de Blas González, F.G.
  • Pérez, C.G.
  • Franco, A.L.G.
  • Beneitez, M.E.V.
  • Ballarín González, Ana
  • Zapata, M.I.F.
  • Suarez, E.G.
  • Ortiz, F.M.
  • Laguno, L.C.P.
  • Gómez, J.L.Q.
  • Pascual, E.R.
  • López, F.R.A.
  • Álvaro, C.C.
  • González, P.C.
  • Hamalainen, S.M.M.
  • Fernández, R.M.
  • Blanco, M.E.R.
  • Arce, C.S.
  • Wiesman, E.C.
  • Galindo, J.O.
  • Marcos, C.L.
  • Borda, S.L.
  • Fernández, J.C.M.
  • Gómez, B.M.
  • de Mingo, E.R.
  • Pascual, J.P.C.
  • Barroso, M.G.
  • Serrano, B.L.
  • Peláez, M.P.M.
  • González, F.P.
  • Salvador, J.S.
  • Yépez, J.D.S.
  • Alonso, A.S.
  • Villalba, M.M.Á.
  • Tapia, P.M.
  • Alcántara, M.A.F.
  • Alonso, M.C.H.
  • González, R.I.
  • Antón, M.A.M.
  • Pérez, M.A.A.
  • Lorenzo, A.A.
  • Medina, R.D.F.
  • Laguna, A.N.L.
  • de Rivera, E.M.C.
  • Flores, I.S.
  • Rodríguez, M.J.S.
  • Isabel, M.S.N.
  • Sánchez, J.M.R.
  • Llanos, P.S.
  • Campillo, L.V.
  • Izquierdo, J.M.
  • Sainz, M.T.
  • Jiménez, M.J.F.
  • García, E.M.
  • Navarro Jiménez, J.M.
  • Gómez, D.G.
  • Mendoza, L.G.
  • de la Mota, Ybancos, Luz Pilar
  • Genafo, J.S.
  • Rodríguez, M.J.A.
  • Garach, E.B.
  • Arteaga, B.C.d.
  • Parrilla, M.D.G.
  • Sánchez Morales, Catalina
  • Chasco, M.M.L.
  • Ríos, I.M.
  • Delgado, E.M.
  • Aurioles, E.M.
  • Ruiz, S.H.
  • Escalante, N.M.
  • Salido, E.L.
  • Torres, M.A.M.
  • Rodríguez, M.L.M.
  • Gálvez, E.P.
  • Torres, J.M.R.
  • Fernández, C.T.
  • Cañavate, M.D.G.M.
  • Mellado, M.M.G.
  • Pradilla, M.V.M.
  • Peña, M.J.C.
  • Fernández, J.L.
  • Romero, V.C.
  • Maqueda, R.Á.
  • Valdés, G.A.
  • Santaella, M.D.
  • Vargas, A.M.F.
  • García, I.G.
  • Rod
Background: Multimorbidity is associated with negative effects both on people''s health and on healthcare systems. A key problem linked to multimorbidity is polypharmacy, which in turn is associated with increased risk of partly preventable adverse effects, including mortality. The Ariadne principles describe a model of care based on a thorough assessment of diseases, treatments (and potential interactions), clinical status, context and preferences of patients with multimorbidity, with the aim of prioritizing and sharing realistic treatment goals that guide an individualized management. The aim of this study is to evaluate the effectiveness of a complex intervention that implements the Ariadne principles in a population of young-old patients with multimorbidity and polypharmacy. The intervention seeks to improve the appropriateness of prescribing in primary care (PC), as measured by the medication appropriateness index (MAI) score at 6 and 12months, as compared with usual care. Methods/Design: Design:pragmatic cluster randomized clinical trial. Unit of randomization: family physician (FP). Unit of analysis: patient. Scope: PC health centres in three autonomous communities: Aragon, Madrid, and Andalusia (Spain). Population: patients aged 65-74years with multimorbidity (=3 chronic diseases) and polypharmacy (=5 drugs prescribed in =3months). Sample size: n=400 (200 per study arm). Intervention: complex intervention based on the implementation of the Ariadne principles with two components: (1) FP training and (2) FP-patient interview. Outcomes: MAI score, health services use, quality of life (Euroqol 5D-5L), pharmacotherapy and adherence to treatment (Morisky-Green, Haynes-Sackett), and clinical and socio-demographic variables. Statistical analysis: primary outcome is the difference in MAI score between T0 and T1 and corresponding 95% confidence interval. Adjustment for confounding factors will be performed by multilevel analysis. All analyses will be carried out in accordance with the intention-to-treat principle. Discussion: It is essential to provide evidence concerning interventions on PC patients with polypharmacy and multimorbidity, conducted in the context of routine clinical practice, and involving young-old patients with significant potential for preventing negative health outcomes. Trial registration: Clinicaltrials.gov, NCT02866799
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Genetic variation analysis in a follow-up study of gastric cancer precursor lesions confirms the association of MUC2 variants with the evolution of the lesions and identifies a significant association with NFKB1 and CD14

  • Companioni, O.
  • Bonet, C.
  • García, N.
  • Ramírez-Lázaro, M.J.
  • Lario, S.
  • Mendoza, J.
  • Adrados, M.M.
  • Poves, E.
  • Espinosa, L.
  • Pozo-Kreilinger, J.J.
  • Ortega, L.
  • Bujanda, L.
  • Cosme, A.
  • Ferrández, A.
  • Muñoz, G.
  • Cuatrecasas, M.
  • Elizalde, I.
  • Andreu, V.
  • Paules, M.J.
  • Madrigal, B.
  • Barrio, J.
  • Berdasco, M.
  • Calvet, X.
  • Sanz-Anquela, J.M.
  • Gisbert, J.P.
  • González, C.A.
  • Sala, N.
Gastric carcinogenesis proceeds through a series of gastric cancer precursor lesions (GCPLs) leading to gastric cancer (GC) development. Although Helicobacter pylori infection initiates this process, genetic factors also play a role. We previously reported that genetic variability in MUC2 is associated with the evolution of GCPLs. In order to replicate previous results in an independent sample series and to explore whether genetic variability in other candidate genes plays a role in the evolution of GCPL, genomic DNA from 559 patients with GCPLs, recruited from 9 Spanish hospitals and followed for a mean of 12 years, was genotyped for 141 SNPs in 29 genes. After follow-up, 45.5% of the lesions remained stable, 37% regressed and 17.5% progressed to a more severe lesion. Genetic association with the evolution of the lesions (progression or regression) was analyzed by multinomial and binomial logistic regression. After correction for multiple comparisons, the results obtained confirmed the inverse association between MUC2 variants and the regression of the lesions. A significant association was also observed between NFKB1 and CD14 variants and the evolution of the lesions; interestingly, this association was with both progression and regression in the same direction, which could reflect the dual role of inflammation in cancer. Stratified analyses according to H. pylori virulence factors indicated some significant and differential effects but none of them passed the FDR test. These results confirm that genetic variability in MUC2, NFKB1 and CD14 may have a role in the evolution of the GCPLs along time and in gastric carcinogenesis.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

The influenza virus NS1A binding protein gene modulates macrophages response to cytokines and phagocytic potential in inflammation

  • Hotter, G.
  • Mastora, C.
  • Jung, M.
  • Brüne, B.
  • Carbonell, T.
  • Josa, C.
  • Pérez-Calvo, J.I.
  • Cruzado, J.M.
  • Guiteras, R.
  • Sola, A.
Macrophages show remarkable phenotypic plasticity in response to environmental signals. Although it is generally less considered, cytoskeletal changes in macrophages influence their phenotype, including phagocytosis and secretion of soluble cytokines. Influenza virus NS1A-binding protein (Ivns1abp) belongs to the Kelch family of proteins that play a central role in actin cytoskeleton dynamics by directly associating with F-actin and by protecting against actin derangement. Due to its role in cytoskeleton preservation, the Ivns1abp gene might be a critical regulator of the macrophage phenotype and function under inflammatory conditions. In this study, we determine that the modulation of the Ivns1abp gene in macrophages could modify resistance to macrophages against inflammation and maintain functional phagocytosis. Our results indicate that inflammatory insults inhibit the Ivns1abp gene, whereby phagocytosis is inhibited and the ability of macrophages to induce proliferation and repair of damaged cells is compromised. Furthermore, our results show that inflammatory insults alter the activity of the transcription factor c-myc, a factor which directly modulates the expression of the Ivns1abp gene. In conclusion, this study demonstrates a central role of lvns1abp in promoting and preserving a reparative macrophage phenotype and resistance to this inflammatory environment.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Low-Cost Assessment of User eXperience Through EEG Signals

  • Cano, S.
  • Araujo, N.
  • Guzman, C.
  • Rusu, C.
  • Albiol-Perez, S.
EEG signals are an important tool for monitoring the brain activity of a person, but equipment, expertise and infrastructure are required. EEG technologies are generally expensive, thus few people are normally able to use them. However, some low-cost technologies are now available. One of these is OPENBCI, but it seems that it is yet to be widely employed in Human-Computer Interaction. In this study, we used OPENBCI technology to capture EEG signals linked to brain activity in ten subjects as they interacted with two video games: Candy Crush and Geometry Dash. The experiment aimed to capture the signals while the players interacted with the video games in several situations. The results show differences due to the absence/presence of sound; players appear to be more relaxed without sound. In addition, consistent analysis of the EEG data, meCue 2.0 and SAM data showed high consistency. The evidence demonstrates that interesting results are able to be gathered based on low-cost EEG (standard) signal-based technologies.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Mesenchymal stromal cells for articular cartilage repair: preclinical studies

  • Fernandez-Pernas, P.
  • Barrachina, L.
  • Marquina, M.
  • Rodellar, C.
  • Arufe, M.C.
  • Costa, C.
Rheumatic diseases such as osteoarthritis (OA) are a major social and economic burden because of the population aging and the lack of curative solutions. An effective cell therapy may be the best treatment option for OA and other cartilage diseases. However, the main cellular strategy used to repair articular cartilage, the transplantation of autologous chondrocytes, is limited to a small number of patients with traumatic lesions. The use of joint replacement after years of disease progression proves the great medical need in current practice. Mesenchymal stromal/stem cells (MSCs) provide an alternative cell source for cartilage regeneration due to numerous advantages, comprising relative ease to isolate and culture, chondrogenic capacity, and anti-inflammatory effects. Initial clinical trials with MSCs have led to encouraging results, but many variables have to be considered to attain true amelioration of disease or repair (type and status of cartilage disease, source and conditions of cells, administration regime, combinatorial approaches). Particularly, allogeneic MSCs are an advantageous cellular product. The animal models chosen for preclinical evaluation are also relevant for successful translation into clinical practice. Considering the limitations in the field, rigorous comparative and validating studies in well-established animal models (including large animals) are still needed to set up the bases for additional clinical trials. The present review of studies performed in small and large animal models should help clarify the applicability of MSC-based therapies for articular cartilage repair.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Cellular Immunity to Predict the Risk of Cytomegalovirus Infection in Kidney Transplantation: A Prospective, Interventional, Multicenter Clinical Trial

  • Jarque, M.
  • Crespo, E.
  • Melilli, E.
  • Gutiérrez, A.
  • Moreso, F.
  • Guirado, L.
  • Revuelta, I.
  • Montero, N.
  • Torras, J.
  • Riera, L.
  • Meneghini, M.
  • Taco, O.
  • Manonelles, A.
  • Paul, J.
  • Seron, D.
  • Facundo, C.
  • Cruzado, J.M.
  • Gil Vernet, S.
  • Grinyó, J.M.
  • Bestard, O.
Background: Improving cytomegalovirus (CMV) immune-risk stratification in kidney transplantation is highly needed to establish guided preventive strategies. Methods: This prospective, interventional, multicenter clinical trial assessed the value of monitoring pretransplant CMV-specific cell-mediated immunity (CMI) using an interferon-γrelease assay to predict CMV infection in kidney transplantation. One hundred sixty donor/recipient CMV-seropositive (D+/R+) patients, stratified by their baseline CMV (immediate-early protein 1)-specific CMI risk, were randomized to receive either preemptive or 3-month antiviral prophylaxis. Also, 15-day posttransplant CMI risk stratification and CMI specific to the 65 kDa phosphoprotein (pp65) CMV antigen were investigated. Immunosuppression consisted of basiliximab, tacrolimus, mycophenolate mofetil, and corticosteroids in 80% of patients, whereas 20% received thymoglobulin induction therapy. Results: Patients at high risk for CMV based on pretransplant CMI developed significantly higher CMV infection rates than those deemed to be at low risk with both preemptive (73.3% vs 44.4%; odds ratio [OR], 3.44 [95% confidence interval {CI}, 1.30-9.08]) and prophylaxis (33.3% vs 4.1%; OR, 11.75 [95% CI, 2.31-59.71]) approaches. The predictive capacity for CMV-specific CMI was only found in basiliximab-treated patients for both preemptive and prophylaxis therapy. Fifteen-day CMI risk stratification better predicted CMV infection (81.3% vs 9.1%; OR, 43.33 [95% CI, 7.89-237.96]). Conclusions: Pretransplant CMV-specific CMI identifies D+/R+ kidney recipients at high risk of developing CMV infection if not receiving T-cell-depleting antibodies. Monitoring CMV-specific CMI soon after transplantation further defines the CMV infection prediction risk. Monitoring CMV-specific CMI may guide decision making regarding the type of CMV preventive strategy in kidney transplantation. Clinical Trials Registration: NCT02550639.